Answers are grounded in this paper and cite their sources.
Administration of an agonistic anti-CD28 mAb paradoxically inhibits donor T cell expansion and prevents graft-versus-host disease (GVHD) in mice.Here we examined the mechanism of anti-CD28-mediated immunosuppression and found that anti-CD28 mAb activated, rather than blocked, CD28-mediated signaling in vivo. Anti-CD28 treatment prevented GVHD by selectively depleting alloantigen-activated donor T cells through apoptosis but spared the T cells that did not recognize recipient alloantigens. Overexpression of Bcl-x L did not protect T cells from depletion and did not affect GVHD prevention after anti-CD28 treatment. Depletion of activated T cells mediated through CD28 did not depend on the expression of death receptors Fas and TNF receptors type I and II, but both the depletion of activated T cells and the suppressive effect of anti-CD28 mAb on GVHD lethality required donor-derived IFN-γ production. This study demonstrates that agonistic Ab's specific for the CD28 costimulatory molecule may be used as novel therapeutic agents to abrogate pathogenic T cell responses by selective depletion of activated T cells.Nonstandard abbreviations used: activation-induced cell death (AICD); C57BL/6 (B6); graft-versus-host disease (GVHD); murine CD28 (mCD28); phycoerythrin (PE); RNase protection assay (RPA); staphylococcal enterotoxin A (SEA); T cell receptor (TCR).
No takes yet. Share an insight, caveat, or question.
Yu et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: